Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $3.2 million.

  • Fortress Biotech's Share-based Compensation fell 5136.16% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.5 million, marking a year-over-year increase of 11095.27%. This contributed to the annual value of $32.6 million for FY2024, which is 9154.97% up from last year.
  • Per Fortress Biotech's latest filing, its Share-based Compensation stood at $3.2 million for Q3 2025, which was down 5136.16% from $16.8 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Share-based Compensation registered a high of $16.8 million during Q2 2025, and its lowest value of $3.2 million during Q3 2025.
  • Its 5-year average for Share-based Compensation is $6.2 million, with a median of $5.0 million in 2024.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 33709.5% in 2024, then crashed by 5136.16% in 2025.
  • Fortress Biotech's Share-based Compensation (Quarter) stood at $7.0 million in 2021, then dropped by 21.76% to $5.5 million in 2022, then tumbled by 32.73% to $3.7 million in 2023, then skyrocketed by 337.1% to $16.2 million in 2024, then plummeted by 80.25% to $3.2 million in 2025.
  • Its Share-based Compensation was $3.2 million in Q3 2025, compared to $16.8 million in Q2 2025 and $6.3 million in Q1 2025.